Carboxypeptidase A6 Promotes the Proliferation and Migration of Hepatocellular Carcinoma by Up-regulating AKT Signaling Pathway

Abstract

Hepatocellular carcinoma (HCC) has a poor treatment prognosis and high mortality worldwide. Understanding the molecular mechanism underlying HCC development would benefit the identification of diagnostic biomarkers and the improvement of the treatment strategies. The expression of carboxypeptidase A6 (CPA6) has been reported in epilepsy and febrile seizures rather than in any type of cancers. However, the function of CPA6 expression in HCC is not yet understood. In this study, we aimed to investigate the clinicopathological significance of the expression of CPA6 in HCC and the underlying mechanisms. We observed that the expression of the CPA6 protein was increased significantly in HCC tissues than in paracancerous tissues. To explore its function in HCC, both gain- and loss-of-function studies demonstrated that CPA6 played a vital role in promoting HCC growth and metastasis. When knocking down CPA6 with shRNA, HCC cell proliferation and migration could be suppressed. Meanwhile, CPA6 overexpression could promote proliferation and migration of HLF cells. Moreover, CPA6 could activate AKT serine/threonine kinase (AKT) signaling pathway as confirmed by Western blotting. In conclusion, our study revealed that CPA6 could promote HCC cell proliferation and migration via AKT-mediated signaling pathway. These findings suggest that CPA6 is a promising diagnostic biomarker and therapeutic target to improve the prognosis of HCC.

Keywords

carboxypeptidase A6 / hepatocellular carcinoma / proliferation / migration / AKT

References

[1] NjeiB, RotmanY, DitahI, et al.. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology, 2015, 61(1): 191-199

[2] BruixJ, ShermanMAmerican Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology, 2011, 53: 1020-1022

[3] LlovetJM, RicciS, MazzaferroV, et al.. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med, 2008, 359(4): 378-390

[4] BelhediN, PerroudN, KaregeF, et al.. Increased CPA6 promoter methylation in focal epilepsy and in febrile seizures. Epilepsy Res, 2014, 108(1): 144-148

[5] LyonsPJ, CallawayMB, FrickerLD. Characterization of carboxypeptidase A6, an extracellular matrix peptidase. J Biol Chem, 2008, 283(11): 7054-7063

[6] LyonsPJ, FrickerLD. Substrate specificity of human carboxypeptidase A6. J Biol Chem, 2010, 285(49): 38234-38242

[7] SapioMR, VessazM, ThomasP, et al.. Novel carboxypeptidase A6 (CPA6) mutations identified in patients with juvenile myoclonic and generalized epilepsy. PLoS One, 2015, 10(4): e0123180

[8] LlovetJM, Hernandez-GeaV. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res, 2014, 20: 2072-2079

[9] LiuQ, TurnerKM, Alfred YungWK, et al.. Role of AKT signaling in DNA repair and clinical response to cancer therapy. Neuro Oncol, 2014, 16(10): 1313-1323

[10] Zhou L, Huang Y, Li J, et al. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol, 27(2):255–261

[11] SapioMR, SalzmannA, VessazM, et al.. Naturally occurring carboxypeptidase A6 mutations: effect on enzyme function and association with epilepsy. J Biol Chem, 2012, 287(51): 42900-42909

[12] PopuloH, LopesJM, SoaresP. The mTOR signaling pathway in human cancer. Int J Mol Sci, 2012, 13(2): 1886-1918

[13] Xie J, Wang X, Proud CG. mTOR inhibitors in cancer therapy. F1000Res, 2016,5

[14] WangZY, ValeraJC, ZhaoXF, et al.. mTOR co-targeting strategies for head and neck cancer therapy. Cancer Metastasis Rev, 2017, 36(3): 491-502

[15] Lucas A, Kim Y, Rivera-Pabon O, et al. Targeting the PI3K/AKT cell survival pathway to induce cell death of HIV-1 infected macrophages with alkylphospholipid compounds. PLoS One, 201,5(9), pii:e13121

[16] PortaC, PaglinoC, MoscaA. Targeting PI3K/AKT/mTOR signaling in cancer. Front Oncol, 2014, 4: 64

[17] LienEC, LyssiotisCA, CantleyLC. Metabolic reprogramming by the PI3K-AKT-mTOR pathway in cancer. Recent Results Cancer Res, 2016, 207: 39-72

[18] WangM, ChenB, ChaiL. Triptolide suppresses the proliferation and induces the apoptosis of nasopharyngeal carcinoma cells via the PI3K/Akt pathway. Oncol Lett, 2019, 17(1): 1372-1378

[19] LiJ, XuH, WangQ, et al.. 14-3-3ζ promotes gliomas cells invasion by regulating Snail through the PI3K/AKT signaling. Cancer Med, 2019, 8(2): 783-794

[20] ChenY, WangG, WangY, et al.. Capn4 regulates migration and invasion of ovarian carcinoma cells via targeting osteopontin-mediated PI3K/AKT signaling pathway. Oncol Lett, 2019, 17(1): 564-570